Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Bioventus (BVS) over the last 6 years, with Q3 2025 value amounting to $42.2 million.

  • Bioventus' Cash & Equivalents fell 211.26% to $42.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.2 million, marking a year-over-year decrease of 211.26%. This contributed to the annual value of $41.6 million for FY2024, which is 1249.32% up from last year.
  • As of Q3 2025, Bioventus' Cash & Equivalents stood at $42.2 million, which was down 211.26% from $32.9 million recorded in Q2 2025.
  • In the past 5 years, Bioventus' Cash & Equivalents ranged from a high of $138.1 million in Q3 2021 and a low of $22.8 million during Q1 2025
  • Over the past 5 years, Bioventus' median Cash & Equivalents value was $37.0 million (recorded in 2023), while the average stood at $50.3 million.
  • As far as peak fluctuations go, Bioventus' Cash & Equivalents soared by 8063.0% in 2021, and later tumbled by 7885.43% in 2022.
  • Bioventus' Cash & Equivalents (Quarter) stood at $43.9 million in 2021, then crashed by 31.29% to $30.2 million in 2022, then increased by 22.45% to $37.0 million in 2023, then grew by 12.49% to $41.6 million in 2024, then increased by 1.4% to $42.2 million in 2025.
  • Its Cash & Equivalents was $42.2 million in Q3 2025, compared to $32.9 million in Q2 2025 and $22.8 million in Q1 2025.